Quantcast

Latest Cancer immunotherapy Stories

2014-08-19 12:28:17

SYDNEY, Aug. 19, 2014 /PRNewswire/ -- Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ("Prima", the "Company") today announced that the abstract entitled, "Trial evaluating overall survival in epithelial ovarian cancer (EOC) patients in second remission with an autologous dendritic cell therapy targeting mucin 1" has been accepted for a poster presentation at the Society for Immunotherapy of Cancer ("SITC") 29th Annual Meeting. The poster will be presented by Prima's...

2014-08-11 08:29:29

HPV Immune Therapy VGX-3100 to Advance into Phase III PLYMOUTH MEETING, Penn., Aug. 11, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013. Total operating expenses were $14.0 million and $26.3 million for the three and six months...

2014-08-11 08:29:09

Patented Technology Enables Accurate Delivery of a Chemotherapeutic Drug to Targeted Tumor Cells, Reducing Drug-related Toxicity without Sacrificing Therapeutic Impact SYDNEY, Aug. 11, 2014 /PRNewswire/ -- EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No....

2014-08-11 08:28:16

TAMPA, Fla., Aug. 11, 2014 /PRNewswire/ -- Morphogenesis Inc., the Tampa-based biotech company that developed the ImmuneFx(TM) cancer vaccine for dogs, cats and horses, announces that it has chosen Florida Veterinary Referral Center & 24-Hour Emergency Hospital in Estero, FL, as the newest exclusive provider of the ImmuneFx(TM) therapy process for companion animals. ImmuneFx(TM) primes and educates the pet's own immune system to recognize and kill cancer cells without harming...

2014-08-06 12:28:13

Study Correlates Immune Response with Improved Survival in Prostate Cancer Patients after Receiving the Antigen Express Novel Immunotherapeutic AE37 WORCESTER, Mass. and TORONTO, Aug. 6, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of a follow-up study from a Phase I clinical trial of the immunotherapeutic agent AE37 in patients with prostate cancer. The study demonstrates an association between a specific immune...

2014-07-16 04:21:39

TUEBINGEN, Germany, July 16, 2014 /PRNewswire/ -- Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics' Human Immunopeptidome Program to identify the most relevant targets for cancer immunotherapies immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer, today announces that it has...

2014-07-10 08:27:19

SEOUL, South Korea, BUSAN, South Korea and SAN FRANCISCO, July 10, 2014 /PRNewswire/ -- SillaJen, Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, announced today a publication that reviews data from the company's oncolytic immunotherapy program, including its lead product Pexa-Vec. Additionally, the publication outlines the rationale for combination therapy with other cancer immunotherapies, such as...

2014-07-08 08:31:51

GRENOBLE, France, July 8, 2014 /PRNewswire/ -- ImmunID announced today that Dr Miguel Perales, Deputy Chief, Adult Bone Marrow Transplant Service and Director, Adult Stem Cell Transplant Fellowship at Memorial Sloan Kettering Cancer Center in New York, is joining its Scientific Advisory Board. http://photos.prnewswire.com/prnvar/20140707/124850 Dr Perales' clinical practice focuses on allogeneic and autologous stem cell transplantation for hematological malignancies as well as novel...

First Antibodies To Treat Cancer In Dogs Developed
2014-07-07 03:10:21

University of Veterinary Medicine Vienna Nearly every second dog develops cancer from the age of ten years onward. A few therapies derived from human medicine are available for dogs. A very successful form of therapy by which antibodies inhibit tumor growth has not been available for animals so far. Scientists at the inter-university Messerli Research Institute of the Vetmeduni Vienna, the Medical University of Vienna, and the University of Vienna have developed, for the first time,...

2014-06-30 12:29:20

Immune Checkpoint Inhibitors Will Hold an Impressive 85 Percent Market Share, According to Findings from Decision Resources Group BURLINGTON, Mass., June 30, 2014 /PRNewswire/ -- Decision Resources Group finds that the immunotherapy market will experience considerable growth through 2022, increasing from $1.1 billion in 2012 to nearly $9 billion in 2022 (corresponding to 23.8 percent annual growth) in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. This impressive...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related